Xenetic Biosciences
XBIO
7 hedge funds and large institutions have $60.7K invested in Xenetic Biosciences in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.03% less ownership
Funds ownership: 1.13% → 1.1% (-0.03%)
24% less capital invested
Capital invested by funds: $79.4K → $60.7K (-$18.7K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.07K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.28K |
| 2 |
Morgan Stanley
New York
|
-$1.03K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $39.5K | – | – | – |
|
|
JEST
2
JTC Employer Solutions Trustee
St Helier,
Jersey
| $10K | – | – | – |
|
|
SPIA
3
Steward Partners Investment Advisory
New York
| $6.55K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3.52K | -$1.28K | -364 | -26% |
|
|
5
UBS Group
Zurich,
Switzerland
| $1.05K | +$1.07K | +305 | New |
|
|
6
Wells Fargo
San Francisco,
California
| $38 | +$4 | +1 | +10% |
|
|
7
Morgan Stanley
New York
| $6 | -$1.03K | -293 | -99% |
|
|
8
Fidelity Investments
Boston,
Massachusetts
| – | -$5 | -1 | Closed |
|
XBIO Hedge Fund Activity: Q4 2023 in Review
7 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2023, worth a combined $60.7K — down 24% from $79.4K a quarter earlier.
Fund positioning in XBIO was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.07K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.28K.
- 7 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $60.7K of Xenetic Biosciences stock for Q4 2023, down 24% quarter-over-quarter.
- 1 fund opened new Xenetic Biosciences positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest Xenetic Biosciences buyer in Q4 2023 was UBS Group, an estimated $1.07K added.
- The largest Xenetic Biosciences seller in Q4 2023 was Tower Research Capital (TRC), an estimated $1.28K sold.
Based on aggregated 13F filings for Q4 2023.